[Development and pre-clinical aspects of pimecrolimus].

about

[Development and pre-clinical aspects of pimecrolimus].

Item

http://www.wikidata.org/entity/Q44420839

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

[Development and pre-clinical aspects of pimecrolimus].

@en

[Development and pre-clinical aspects of pimecrolimus].

@nl

type

Item

label

[Development and pre-clinical aspects of pimecrolimus].

@en

[Development and pre-clinical aspects of pimecrolimus].

@nl

prefLabel

[Development and pre-clinical aspects of pimecrolimus].

@en

[Development and pre-clinical aspects of pimecrolimus].

@nl

P1476

[Development and pre-clinical aspects of pimecrolimus].

@en

P2093

A Stütz

http://www.w3.org/2001/XMLSchema#string

J G Meingassner

http://www.w3.org/2001/XMLSchema#string

M Grassberger

http://www.w3.org/2001/XMLSchema#string

P2860

A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology

Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial.

Pimecrolimus (Elidel, SDZ ASM 981)--preclinical pharmacologic profile and skin selectivity.

Cyclosporine in dermatology.

Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner.

The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study.

The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils.

Pimecrolimus inhibits up-regulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells.

Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated.

P2888

s00105-003-0519-0

P304

405-412

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00105-003-0519-0

http://www.w3.org/2001/XMLSchema#string

P407

Af-Jarmal

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2003-04-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12719859

http://www.w3.org/2001/XMLSchema#string